ArticleJournal of hepatocellular carcinoma2025
Adjuvant Sintilimab with or without Anti-VEGF Therapy After Resection in Hepatocellular Carcinoma with Microvascular Invasion: A Multicenter Retrospective Study.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with hepatocellular carcinoma (HCC) and microvascular invasion (MVI) face high post-resection relapse risk. Whether adjuvant PD-1 alone or with anti-vascular endothelial growth factor (anti-VEGF) improves outcomes remains uncertain. Methods: Between 1 January 2022 and 1 January 2023, 170 consecutive patients from three Chinese centers were retrospectively reviewed. After resection, 69 received observation, 46 received intravenous sintilimab, and 55 received sintilimab plus either oral lenvatinib or intravenous bevacizumab biosimilar. Recurrence-free survival (RFS) was analyzed with Kaplan-Meier estimates and Cox models. Results: Median follow-up was 24.7 months. Recurrence or death occurred in 42/69 (60.9%) observation patients, 19/46 (41.3%) sintilimab patients, and 23/55 (41.8%) combination patients. Median RFS was 16.1 months after observation, versus 29.5 months with sintilimab (hazard ratio=0.55, 95% confidence interval=0.32-0.95; P = 0.033) and 30.5 months with sintilimab plus anti-VEGF therapy (hazard ratio=0.55, 95% confidence interval=0.33-0.92; P = 0.023). One- and two-year RFS rates were 58.0% and 40.0% for observation, 73.9% and 66.6% for sintilimab, and 81.8% and 63.0% for combination therapy. Overall survival analysis is immature, median overall survival has not been reached in any group. Conclusion: Adjuvant sintilimab, with or without anti-VEGF therapy, significantly prolonged RFS compared with surgery alone in patients with MVI-positive HCC. The magnitude of benefit was comparable between monotherapy and combination therapy, indicating that routine addition of anti-VEGF therapy may not be necessary for all patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.